| A | B | C | D | E | F | G | H | I | J | K | L | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ||||||||||||
| 2 | Name | Indication | MOA | Economics | Approved | Price | 128.06 | |||||
| 3 | Xywav (Ca, Mg, K, Na oxybate) | IH | 7/21/2020 | Shares | 64.004791 | Q123 | ||||||
| 4 | Xyrem (Na oxybate) | IH | 7/17/2002 | MC | 8196.45353546 | |||||||
| 5 | Rylaze (asparaginase) | ALL | Cash | 1167.911 | Q123 | |||||||
| 6 | Zepzelca (lurbinectedin) | SCLC | Debt | 5720.662 | Q123 | |||||||
| 7 | Epidyolex | TSC/Dravet | 9/28/2018 | EV | 12749.20453546 | |||||||
| 8 | Phase | |||||||||||
| 9 | JZP815 | pan-RAF | I | |||||||||
| 10 | zanidatamab | HER2 | ZYME | |||||||||
| 11 | suvecaltamide | Parkinson's | T-type Ca inhibitor | |||||||||
| 12 | JZP441 | orexin-2 agonist | I | |||||||||
| 13 | JZP150 | PTSD | FAAH |